What changed when Part D price concessions moved to the point of sale
For years, most independent pharmacists have contended with retroactive pharmacy price concessions in Medicare Part D plans. These "DIR fees" were often deducted months after a prescription was dispensed, making it difficult to predict profitability or even know which fills would end up in the red. Recent changes now require that all pharmacy price concessions be reflected at the point of sale, rather than clawed back later.
This shift brings some welcome clarity. Pharmacies now see the true reimbursement at adjudication, letting staff know upfront if a claim pays below cost. There is less risk of negative surprises on future remittance advices. Pharmacies can also communicate more transparently with patients about copays, as the numbers on the register match those on the claim.
However, the adjustment comes with a tradeoff. Since lower fees are baked into each transaction, net reimbursements have dropped for many fills. Pharmacies are feeling the squeeze immediately, not months down the line. In some cases, fills that previously broke even after reconciling, now result in a loss the moment they are dispensed. The administrative headache of post-point-of-sale reconciliations is gone, but the margin challenge is immediate and ongoing.
Keep reading: A Winter Ride-Along on a Rural Pharmacy Delivery Route
NADAC as a benchmark and the case for cost plus dispensing fees
The National Average Drug Acquisition Cost, or NADAC, has grown in influence as a pricing benchmark. NADAC tracks what pharmacies actually pay wholesalers for medications, updating regularly to reflect market shifts. Some payers and Medicaid programs have moved toward using NADAC as the basis for ingredient cost reimbursement, shifting away from older benchmarks like AWP or WAC that don't track real pharmacy acquisition prices as closely.
For independents, NADAC's movement toward actual acquisition cost helps prevent situations where reimbursement is far below cost, especially for generics that can fluctuate quickly. However, NADAC alone does not account for every pharmacy's overhead, staffing, or unique purchasing circumstances. To cover these costs, most advocates argue for a "cost plus dispensing fee" model: NADAC (or invoice price) plus a flat professional fee that reflects the cost of providing pharmacy services.
Dispensing fees in many states remain low, often set years ago and not adjusted for inflation or wage increases. Some state Medicaid programs have recently reviewed and updated their dispensing fees, but in most commercial arrangements, the fee is bundled in or not disclosed at all. Without a meaningful fee, it is difficult for community pharmacies to cover the costs of maintaining inventory, staff, and compliance.
The case for a cost plus model is gaining support among pharmacy organizations and some state Medicaid agencies. The key challenge remains convincing payers and PBMs to recognize the true cost of dispensing, not just the ingredient price. Until then, pharmacies must watch reimbursement benchmarks closely, ensure their acquisition costs align with NADAC, and challenge any payments that fall below cost.
State PBM laws: licensure, audit limits and any willing pharmacy provisions
States have increasingly stepped in to regulate pharmacy benefit managers (PBMs), addressing longstanding complaints from independents about opaque contracts and unfair business practices. PBM licensure is now required in many states, forcing PBMs to register with the insurance department and comply with transparency rules. This gives state regulators more oversight and creates a path for complaints when PBMs violate state law.
Audit limits and transparency improvements
Pharmacy audits by PBMs have long been a pain point, with some independents reporting excessive paperwork and "fishing expeditions" for minor errors. Recent state laws cap how often audits can be conducted, limit recoupment to true fraud or overpayment, and require that pharmacies be given a chance to correct clerical mistakes. These rules help level the playing field, though enforcement varies by state.
Any willing provider and network access
"Any willing pharmacy" provisions are another area of reform. These laws require PBMs to allow any pharmacy willing to meet network terms and conditions to participate. While the intent is to keep networks open and prevent steering to affiliated mail order or chain locations, PBMs sometimes set terms that are difficult for independents to meet. Still, these provisions have helped some independents retain access to plan networks and keep patients from being forced elsewhere.
State PBM laws are evolving, and legal challenges from PBMs are ongoing. Nevertheless, independent pharmacies should monitor state legislation, understand their rights under new laws, and document any violations for potential review by regulators.
Keep reading: How to Build a Med Sync Program in an Independent Pharmacy
Medicaid managed care carve outs and fee for service pricing
Medicaid reimbursement is a lifeline for many independents, but the way Medicaid pays for prescriptions varies by state. Managed care organizations (MCOs) now handle Medicaid pharmacy benefits in most states, contracting with PBMs to set reimbursement rates and dictate network terms. This has led to wide variation in payment rates, sometimes below acquisition cost for generics or specialty medications.
In response, several states have "carved out" the pharmacy benefit from managed care, returning to a traditional fee for service (FFS) model where the state Medicaid agency pays pharmacies directly. The goal is to improve transparency, set fairer reimbursement based on NADAC plus a dispensing fee, and reduce spread pricing by PBMs. States like New York and California have recently moved in this direction, and others are considering it.
For pharmacy owners, a carve out can mean higher and more predictable reimbursements, but it also comes with new administrative requirements and updated billing systems. Pharmacies must stay informed as states debate and implement these changes, since a switch from MCO to FFS can happen on fixed dates and requires prompt adaptation to new formularies and claims submission methods.
Fee for service Medicaid often uses NADAC as the ingredient benchmark, paired with a state-set dispensing fee. Pharmacies should review their most common Medicaid fills and verify that current reimbursement covers both drug cost and operational overhead. If it does not, documentation and appeals to the Medicaid agency may be necessary.
Clinical services as revenue: immunizations, test and treat, and billing paths
With prescription margins under pressure, independents are expanding their clinical services to build new revenue streams. Immunizations remain the most common service, with pharmacies administering vaccines for flu, COVID-19, shingles, and more. These services provide not only a dispensing fee but also increased foot traffic and opportunities to counsel patients.
Some states now allow pharmacists to test and treat for conditions like strep throat, influenza, and even minor skin infections. These "test and treat" pathways let pharmacies bill third-party payers or charge cash, expanding the scope of clinical care and providing a buffer against shrinking traditional margins. Reimbursement varies: some payers offer a set fee per clinical encounter, while others may bundle it with dispensing.
Billing and credentialing challenges
Billing for clinical services can be complex. Pharmacies must navigate payer credentialing, select the right codes, and submit claims that track with medical billing requirements. Not all payers accept pharmacy claims for clinical services, and some require contracting processes that take weeks or months. Independents often need to invest in billing software or partner with third-party billing services to maximize reimbursement and avoid denied claims.
Despite the challenges, clinical services are becoming an essential part of the independent pharmacy's revenue mix. Staff training, workflow redesign, and patient outreach can help ensure these services are promoted and delivered efficiently.
See how PillRoute handles this for independent pharmacy
340B contract pharmacy pressure and what it means for independents
The 340B Drug Pricing Program allows certain hospitals and clinics to purchase drugs at deep discounts, with independent pharmacies often serving as contract pharmacies to dispense on behalf of these covered entities. In recent years, several drug manufacturers have restricted shipments to contract pharmacies, requiring claims data or limiting participation to a single location per covered entity.
These restrictions have squeezed 340B revenue for many independents, especially those in rural or underserved areas where hospital partnerships are vital. Pharmacies have faced abrupt contract terminations, reduced access to discounted inventory, and the need to invest in more robust compliance and tracking systems to satisfy manufacturer and payer requirements.
Some states have acted to protect contract pharmacy arrangements, passing laws that require manufacturers to honor shipments or prohibit discrimination against 340B entities. However, court challenges and shifting federal guidance mean the outlook remains uncertain. Independents relying on 340B revenue should monitor manufacturer notices, maintain close communication with covered entity partners, and review contracts regularly to ensure ongoing participation and compliance.
As 340B restrictions continue, pharmacies must evaluate the share of their business tied to these contracts and assess the impact of any new manufacturer policies. Diversifying income sources and staying informed on regulatory developments will help reduce risk.
Where delivery, adherence work and cash pay lines fit the next few years
With reimbursement under pressure from multiple directions, independent pharmacies are doubling down on services that build patient loyalty and create value beyond the prescription claim. Local delivery, medication synchronization, and adherence packaging are three areas where independents can stand out against chain and mail order competitors.
Delivery services meet a critical need for patients who are homebound, busy, or managing complex regimens. By ensuring timely access to medications, pharmacies improve adherence and outcomes, which can lead to better performance on payer quality measures. Medication synchronization programs align patient refills to a single pick-up or delivery date, reducing missed doses and simplifying operations. Synchronization also helps smooth workload for staff and makes route planning more efficient.
Cash pay business remains important, especially as some patients face high deductibles or find themselves between insurance plans. Pharmacies can offer competitive prices on select generics, supplementing insurance-based revenue and serving patients who might otherwise seek alternatives online or at big box stores. Transparent pricing, clear communication, and high-touch service help build trust and repeat business.
As reimbursement models evolve, pharmacies that streamline delivery logistics, capture required signatures, and manage refill calls efficiently can maximize each patient interaction. Tools that combine medication synchronization, delivery route planning, and workflow management can help independents stay competitive and focused on patient care, even as traditional margins tighten.
